68 results
8-K
EX-99.1
GOSS
Gossamer Bio Inc
20 Jul 23
Interim TORREY OLE Update and PROSERA Phase 3 Design July 2023
7:50am
Summary of OLE findings to date: Differentiated efficacy and safety profile emerging Continued improvement in reduction of PVR 30 patients with Week 72 … of effect in Phase 3 target population Attractive safety profile for chronic treatment Regulatory feedback supportive of single registrational study
8-K
EX-99.1
GOSS
Gossamer Bio Inc
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
authorities and continuing our discussions with potential strategic partners.
LEDA Safety and Tolerability Results
The incidence of adverse events … with GB001 40 mg vs. placebo over 16 weeks. Neither the primary nor the secondary endpoints of the trial were met. The safety and tolerability of GB001
8-K
EX-99.2
GOSS
Gossamer Bio Inc
14 May 19
Gossamer Bio Announces First Quarter 2019 Financial Results
7:31am
patients have received at least 1 dose of GB001 with no clinically significant safety findings(1) Patent protection out to 2031(2) GB001
Role and Biology … and safety of GB001 as maintenance therapy in adult subjects with moderate to severe asthma Status: Enrolling, Initiated October 2018 GB001
CRS and CSU
8-K
EX-99.2
GOSS
Gossamer Bio Inc
13 Oct 20
Gossamer Bio Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis
7:40am
or strategic alternatives; topline results Gossamer reports are based on preliminary analysis of key efficacy and safety data, and such data may change … to evaluate the efficacy and safety of GB001 as maintenance therapy in adult patients with moderate-to-severe asthma Patient Population 480 adult
10-K
jl4dp6x krhy
22 Mar 19
Annual report
4:45pm
8-K
EX-99.1
fa405tfrd87651
12 May 20
Gossamer Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update
4:18pm
8-K
EX-99.1
wdodd
6 Dec 22
Other Events
7:36am
DRSLTR
ofv0e 4nkb3
29 Nov 18
Correspondence regarding draft registration statement
12:00am
S-1/A
jhtnih531x5
23 Jan 19
IPO registration (amended)
4:39pm
DRS
88h948nq4yb36s0
11 Oct 18
Draft registration statement
12:00am
DRS/A
0te3puk9h7oh
29 Nov 18
Draft registration statement (amended)
12:00am
424B4
5i41tlogko555nw 6e2
8 Feb 19
Prospectus supplement with pricing info
4:40pm
S-1
mv9ys1
21 Dec 18
IPO registration
4:39pm
8-K
9k2w0 gya9a
6 Dec 22
Other Events
7:36am
8-K
EX-99.1
bbgbi
14 May 19
Gossamer Bio Announces First Quarter 2019 Financial Results
7:31am